Peptide Inhibitors of the alpha-Cobratoxin-Nicotinic Acetylcholine Receptor Interaction
Autor(en): | Lynagh, Timothy Kiontke, Stephan Meyhoff-Madsen, Maria Gless, Bengt H. Johannesen, Jonas Kattelmann, Sabrina Christiansen, Anders Dufva, Martin Laustsen, Andreas H. Devkota, Kanchan Olsen, Christian A. Kuemmel, Daniel Pless, Stephan Alexander Lohse, Brian |
Stichwörter: | Chemistry, Medicinal; Pharmacology & Pharmacy | Erscheinungsdatum: | 2020 | Herausgeber: | AMER CHEMICAL SOC | Journal: | JOURNAL OF MEDICINAL CHEMISTRY | Volumen: | 63 | Ausgabe: | 22 | Startseite: | 13709 | Seitenende: | 13718 | Zusammenfassung: | Venomous snakebites cause >100 000 deaths every year, in many cases via potent depression of human neuromuscular signaling by snake alpha-neurotoxins. Emergency therapy still relies on antibody-based antivenom, hampered by poor access, frequent adverse reactions, and cumbersome production/purification. Combining high-throughput discovery and subsequent structure-function characterization, we present simple peptides that bind alpha-cobratoxin (alpha-Cbtx) and prevent its inhibition of nicotinic acetylcholine receptors (nAChRs) as a lead for the development of alternative antivenoms. Candidate peptides were identified by phage display and deep sequencing, and hits were characterized by electrophysiological recordings, leading to an 8-mer peptide that prevented alpha-Cbtx inhibition of nAChRs. We also solved the peptide: alpha-Cbtx cocrystal structure, revealing that the peptide, although of unique primary sequence, binds to alpha-Cbtx by mimicking structural features of the nAChR binding pocket. This demonstrates the potential of small peptides to neutralize lethal snake toxins in vitro, establishing a potential route to simple, synthetic, low-cost antivenoms. |
ISSN: | 00222623 | DOI: | 10.1021/acs.jmedchem.0c01202 |
Zur Langanzeige
Seitenaufrufe
3
Letzte Woche
1
1
Letzter Monat
1
1
geprüft am 13.05.2024